Silkim Pharma
Novel Drugs Targeting Inflammatory Pathologies
Startup Mature Health Tech & Life Sciences Est. 2013
Total Raised
Undisclosed
Mature
Last Round
Undisclosed
Team
2
1-10 employees
Confidence
98/100
News
1
articles
Patents
1
About
Silkim Pharma has developed a novel, protected platform of drugs for proven treatments of multiple indications. The company's platform is the result of extensive investigation of animal models of human diseases. Members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Biologicals
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B
Tags
drug-developmentinflammatory-diseasesdegenerative-diseasestreatmentspharmaceuticalsdrug-discoverycrohn's-diseasediabetesanti-inflammatory
News (1)
May 24, 2020 · jlm-biocity.org
growth-positive
Silkim Pharma's New Drug Against Coronavirus Receives Response from FDA in Record Time!! - JLM-BioCity
Investment
Details
Product Stage
Released
Employees
1-10
Exact Count
1
District
Center District
Founded
2013
Registrar
514894195
Crunchbase
silkim-pharma
Locations
Ranana, Israel
Links
Website
LinkedIn
Twitter
Facebook
Admin
Last Update
May 28, 2021
Verified by
Yanina Wainscheinker
Claimed
Yes
Missing
video or image, funding rounds, markets
Team (2)
Dror Chevion
Co-founder & CEO
Founder
Prof. Mordechai (Mottie) Chevion
Co-founder & CSO
Founder
Internal
Created by
Yanina Wainscheinker (yanina.wain@gmail.com)
Created
2020-04-22T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wain@gmail.com)